C2 PHARMA, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), recently celebrated its 10th year as a company and will also be celebrating its decade-long attendance at CPHI worldwide. The company recently launched Naphazoline Hydrochloride, expanding its ophthalmic API portfolio, while it also received approval for a Certificate of Suitability (CEP) for Tropicamide.
"Our global leadership in ophthalmic APIs is underpinned by our willingness to set the bar higher at all levels," states Andrew Badrot, CEO of C2 PHARMA. "We are committed to providing our customers APIs with unparalleled cost-to-quality, cost-to-reliability, and always stay focused on how to improve their speed-to-market. Through excellence and hard work, we ensure that our clients receive the best value for money, maintaining our position at the forefront of the API industry."
C2 PHARMA’s portfolio expansion will continue into the upcoming 24-month period and include the following product launches:
- Naphazoline Nitrate
- Timolol Maleate
- Dorzolamide Hydrochloride
- Brinzolamide and Brinzolamide (sterile)
- Oxybuprocaine Hydrochloride
- Indocyanine Green
C2 PHARMA’s regulatory filings under submission include:
- Atropine Sulfate (CADIFA)
- Homatropine Methylbromide (CADIFA)
- Naphazoline Hydrochloride (CEP, US-DMF, CADIFA)
- Brimonidine Tartrate (C-DMF, CADIFA)
- Latanoprost (CEP)
- Tropicamide (C-DMF, J-DMF)
A full list of C2 PHARMA’s products and filings can be found here, with the R&D pipeline available here.
The company will exhibit at CPHI Worldwide 2024 in Milan from October 8th to 10th in Hall 4, Booth A11, with its affiliate, Logistics4Pharma.
To schedule a meeting, please email info@c2pharma.com.
